01877 Shanghai Junshi Biosciences (H)

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints
EN
08/10/2020

Underlying

01877Shanghai Junshi Biosciences (H)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shanghai Junshi Biosciences (H)

 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (the “NMPA”) has approved two supplemental new drug applications for the ongericimab injection (a recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA (君适达®)) for: 1) adult ...

May 27, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the ...

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“NDA”) for toripalimab (trade name: TUOYI®) as the first-line treatment for unresectable or metastatic melanoma has been approved by the National Medical Products Administrat...

April 25, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces 2024 Full Year Financial Results and Prov...

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue of Junshi Biosciences was approximately RMB1,948 million in 2024, representing an increase of approxima...

March 29, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Junshi Biosciences Announces Toripalimab’s Approval in Singapore SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastati...

March 27, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combi...

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab, in com...

March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch